Skip Nav Destination
Issues
1 September 1999
ISSN 1078-0432
EISSN 1557-3265
Editorial
Minireview
Advances in Brief
Clinical Trials
Aerosol Granulocyte Macrophage-Colony Stimulating Factor: A Low Toxicity, Lung-specific Biological Therapy in Patients with Lung Metastases1
Peter M. Anderson; Svetomir N. Markovic; Jeffery A. Sloan; Mary Lou Clawson; Mark Wylam; Carola A. S. Arndt; William A. Smithson; Patrick Burch; Michael Gornet; Emel Rahman
Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration
Robert M. Conry; Muhamad B. Khazaeli; Mansoor N. Saleh; Karen O. Allen; Daunte L. Barlow; Susan E. Moore; Dayle Craig; Ramin B. Arani; Jeffrey Schlom; Albert F. LoBuglio
Interleukin 2 Gene Therapy of Colorectal Carcinoma with Autologous Irradiated Tumor Cells and GeneticallyEngineered Fibroblasts: A Phase I Study1
Robert E. Sobol; Daniel L. Shawler; Colette Carson; Charles Van Beveren; Dan Mercola; Habib Fakhrai; Mia A. Garrett; Robert Barone; Paul Goldfarb; Richard M. Bartholomew; Steven Brostoff; Dennis J. Carlo; Ivor Royston; Daniel P. Gold
A Phase I Study of Raltitrexed, an Antifolate Thymidylate Synthase Inhibitor, in Adult Patients with Advanced Solid Tumors
Jean L. Grem; J. Mel Sorensen; Ellen Cullen; Chris H. Takimoto; Seth M. Steinberg; Alice P. Chen; J. Michael Hamilton; Susan G. Arbuck; Nanette McAtee; David Lawrence; Barry Goldspiel; Patrick G. Johnston; Carmen J. Allegra
A Phase II Study of Adjuvant Therapy with Anti-B4-blocked Ricin after Autologous Bone Marrow Transplantation for Patients with Relapsed B-Cell Non-Hodgkin’s Lymphoma1
Michael L. Grossbard; Pratik S. Multani; Arnold S. Freedman; Steven O’Day; John G. Gribben; Catherine Rhuda; Donna Neuberg; Lee M. Nadler
A Pilot Study of Interferon α-2a, Fluorouracil, and Leucovorin Given with Granulocyte-Macrophage Colony Stimulating Factor in Advanced Gastrointestinal Adenocarcinoma
Jeremy D. Shapiro; Nancy Harold; Chris Takimoto; J. Michael Hamilton; David Vaughn; Alice Chen; Seth M. Steinberg; David Liewehr; Carmen Allegra; Brian Monahan; Alex Lash; Frank Grollman; Donald Flemming; Katherine Behan; Patrick G. Johnston; Daniel Haller; Mary Quinn; Geraldine Morrison; Jean L. Grem
Molecular Oncology, Markers, Clinical Correlates
Expression of p21WAF1/Cip1 in the p53-dependent Pathway Is Related to Prognosis in Patients with Advanced Esophageal Carcinoma1
Shoji Natsugoe; Saburo Nakashima; Masataka Matsumoto; Che Xiangming; Hiroshi Okumura; Fumio Kijima; Sumiya Ishigami; Yuji Takebayashi; Masamichi Baba; Sonshin Takao; Takashi Aikou
A Novel Putative Low-Affinity Insulin-like Growth Factor-binding Protein, LIBC (Lost in Inflammatory Breast Cancer), and RhoC GTPase Correlate with the Inflammatory Breast Cancer Phenotype1
Kenneth L. van Golen; Seena Davies; Zhi Fen Wu; YunFang Wang; Corazon D. Bucana; Holly Root; Settara Chandrasekharappa; Myla Strawderman; Stephen P. Ethier; Sofia D. Merajver
Experimental Therapeutics, Preclinical Pharmacology
Gains of 1q21–q22 and 13q12–q14 Are Potential Indicators for Resistance to Cisplatin-based Chemotherapy in Ovarian Cancer Patients1
Kazuya Kudoh; Masashi Takano; Tomoyuki Koshikawa; Misako Hirai; Sadao Yoshida; Yoshinori Mano; Kenji Yamamoto; Kenji Ishii; Tsunekazu Kita; Yoshihiro Kikuchi; Ichiro Nagata; Masanao Miwa; Kazuhiko Uchida
Impact of Polyglutamation on Sensitivity to Raltitrexed and Methotrexate in Relation to Drug-induced Inhibition of de Novo Thymidylate and Purine Biosynthesis in CCRF-CEM Cell Lines1
Matthew J. Barnes; Edward J. Estlin; Gordon A. Taylor; G. Wynne Aherne; A. Hardcastle; J. J. McGuire; Joanne A. Calvete; John Lunec; Andrew D. J. Pearson; David R. Newell
Low-Dose Cisplatin and 5-Fluorouracil in Combination CanRepress Increased Gene Expression of Cellular Resistance Determinants to Themselves1
Masahiko Nishiyama; Wataru Yamamoto; Ji-Seon Park; Ryo Okamoto; Hoken Hanaoka; Hiroshi Takano; Norio Saito; Masaaki Matsukawa; Tetsuhiko Shirasaka; Minoru Kurihara
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.